Name

Teva Santé

Legal name

Teva Santé SAS

Website

https://teva-sante.fr

Company type

Private

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Professional, Scientific, and Technical Services (54), Scientific Research and Development Services (5417), Health Care and Social Assistance (62)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Patient Support Programs & Device/Vaccine Vigilance (PSP/PSUR support) (HLAGALAK)

akta.pro secondary industries

Safety/Pharmacovigilance (PV) & Clinical Safety Systems (HLACAOAH), Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN), Safety Database Operations & Hosting (Argus/ARISg/Oracle) (HLAGALAB)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Specialty pharmaceuticals
• Pharmaceutical distribution
• Patient support programs

Headquarters

HQ city

La Défense

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Medications: Production and sale of generic pharmaceutical products, representing the core business foundation. Teva is a global leader in generics with wide therapeutic coverage.
2. Biosimilars: Development and commercialization of biosimilar medications following patent expiration of reference biologics, expanding access to biological treatments at reduced costs.
3. Innovative/Specialty Medications: Development and distribution of innovative medications addressing specialized therapeutic needs in neuroscience, respiratory, and oncology areas.
4. Over-the-Counter (OTC) Products: Self-medication products available without prescription, distributed through pharmacy networks.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Teva Santé SAS is the French subsidiary of Teva Pharmaceutical Industries Ltd., distributing a comprehensive portfolio of generic medications, biosimilars, specialty pharmaceuticals, and over-the-counter products in France. The company ranks 4th among French pharmaceutical laboratories by number of medicines distributed, covering over 120 pathologies across therapeutic areas including neurology, pneumology, oncology, and gastroenterology. The offering is complemented by patient support programs, mobile health applications (MonTeva, Tifanie), caregiver resources, and digital adherence tools.

Product overview

Teva Santé operates as a pharmaceutical company offering a unified portfolio of generic medications, specialty medicines, biosimilars, and over-the-counter products. The core offering includes generic medications (ranked 4th in France by distribution volume), biosimilars, and specialty medicines for neuroscience, respiratory, oncology, and gastroenterology conditions. Digital patient support is provided through the MonTeva mobile app, the Tifanie app for functional bowel disorders, and the Mieux Vivre avec la SEP patient education website. The Marguerite program provides adherence support for elderly patients through pharmacists. Broader patient education includes risk reduction tools, condition-specific brochures, and caregiver support materials developed with partners like Je T'Aide.

Differentiator

Problem solved

Functional benefit

Brands

• MonTeva: Mobile application for patients
• MonTeva

Products and services

• Generic Medications Portfolio Comprehensive range of generic medications covering multiple therapeutic areas including neurology, pneumology, oncology, and gastroenterology. Distributed through pharmacy networks across France, serving over 120 pathologies. Teva Santé is ranked 4th among French laboratories by number of medicines distributed.
• Biosimilars Biosimilar medicines that provide affordable alternatives to reference biological products whose patents have expired. Teva participates in a biosimilar think tank consortium with Amgen, Boehringer Ingelheim, Pfizer, and Sandoz.
• Specialty Medicines Specialized medications for complex conditions including neuroscience treatments (tardive dyskinesia, schizophrenia, migraine, multiple sclerosis), asthma, nausea/vomiting, and cystic fibrosis.
• Over-the-Counter (OTC) Medicines Self-medication products available without prescription for minor ailments, distributed through community pharmacy networks in France.
• MonTeva Mobile Application Mobile application providing patients access to Teva health resources, medication information, and patient support services from mobile devices. Available via patient portal at mon-teva.fr.
• Marguerite Program Medication adherence program for elderly polymedicated patients, including a health binder tool that enables pharmacists to better support patients in their care journey.
• Tifanie Application Mobile application for patients with Functional Bowel Disorders (FBD/IBS), providing educational content and symptom tracking. Certified with the MedappCare quality label for connected health.
• Mieux Vivre avec la SEP Comprehensive patient education website for multiple sclerosis patients featuring over 60 expert-validated pages, 70+ video responses, interactive modules, and 30+ thematic topics.

Quantifiable outcome

• 120+ pathologies covered in France
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability4 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• Collectif Je T'aide (formerly Journée des aidants)coreStrategic or Co-development PartnerTeva Santé partners with the Collectif Je T'aide to support the 11 million caregivers in France. The partnership includes the production of the 'Vous l'aimez, vous vous aidez' brochure and other caregiver support materials distributed through pharmacies and medical offices. The collaboration also includes the 'Box Aidants' distributed in pharmacies.
• IQVIAmajorTechnology or IntegrationIQVIA Operations France serves as the data processor for Teva Santé's clinical research studies, including the Valproate AVALON study accessing SNDS health data. IQVIA provides secure data infrastructure and epidemiological expertise for health research projects.
• Biosimilaires Think Tank (Amgen, Boehringer Ingelheim, Pfizer, Sandoz)minorStrategic or Co-development PartnerTeva joined with Amgen, Boehringer Ingelheim, Pfizer, and Sandoz to create a think tank addressing societal, scientific, and medical issues related to biosimilar medications. The group meets 5 times yearly to discuss patient information, economic aspects, and therapeutic co-decision-making.
• WefightminorStrategic or Co-development PartnerPartnership with AI health startup Wefight to support cancer patients through the Vik companion application. The partnership includes collaboration with Mon réseau Cancer du sein patient association to develop AI-powered patient support tools.
• Vaincre la MucoviscidoseGTM or Marketing PartnerPartnership with cystic fibrosis patient association to publish caregiver information brochures about the disease, distributed through physicians and pharmacists.
• Tulipe (Humanitarian Health Association)minorGTM or Marketing PartnerTeva contributes donated medications to the Tulipe association for emergency humanitarian aid, including the 3-ton medical supply shipment to Caribbean hurricane victims.

Scale indicators12 records

Recent moves2 records

Broad incumbents

• Sanofi: France's largest pharmaceutical company and historically one of Teva's largest French customers. Comparable as a domestic French pharma major with overlapping generics (Winthrop/Sanofi Generics) and specialty franchises, plus hospital channel presence.
• Merck Génériques (Merck KGaA): German-headquartered science and technology conglomerate with a French generics franchise. Comparable as a broader-company peer whose life sciences division competes with Teva in biosimilars, fertility, and neurology specialty areas in France.

Direct peers

• Krka: Slovenian-headquartered European generics manufacturer with strong presence in France via its generics business. Comparable as a multi-therapy-area European generics peer competing for French pharmacy group contracts.
• Sandoz: Global generics and biosimilars leader spun off from Novartis in 2023, headquartered in Basel with strong European generics footprint. Directly comparable as the other top-tier European generics manufacturer competing with Teva in French pharmacy listings and biosimilar launches.
• Biogaran: French generics leader historically ranked 1st in France by volume (Servier subsidiary). Direct competitor for French pharmacy shelf space, ANSM-listed generics, and CEPS pricing negotiations — the most direct head-to-head rival for Teva Santé in the French market.
• EG Labo (Stada): French subsidiary of Stada Arzneimittel, another major European generics manufacturer. Direct competitor in French pharmacy channel with similar specialty and OTC adjacencies.
• Arrow Génériques (Aurobindo): French generics subsidiary of Aurobindo Pharma (India), one of the top generics distributors in France. Directly competes with Teva Santé on pharmacy listings, with comparable therapeutic coverage and aggressive pricing posture.
• Viatris (formerly Mylan): Global generics and specialty player formed via Mylan-Pfizer Upjohn combination; operates a significant French generics franchise. Comparable as a multi-country generics distributor with overlap in biosimilars, complex generics, and European pharmacy channel sales.
• Zentiva: European generics manufacturer owned by Sanofi, headquartered in Prague. Comparable as a multi-country generics player competing directly in French hospital and retail pharmacy channels with biosimilar ambitions.

Regional players

• Polpharma: Polish generics manufacturer with growing presence in European pharmacy markets. Comparable as a Central European generics peer with adjacent geographic footprint, though smaller in France.

Market position

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/TevaSante
• LinkedInlinkedin.com/company/teva-sante
• Instagraminstagram.com/tevasante
• Xx.com/TevaSante

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Santé